Bentley Pharmaceuticals Revs Up Production Efforts With Cardinal Health

Bentley (BNT) has inked an agreement to use one of Cardinal Health's (CAH) facilities for the scale-up and production of supplies for its intranasal insulin drug candidate currently in clinical trials.

On Friday, BNT announced that it was recognized as one of the 50 fastest growing life science's companies in New England.

BNT stock has been on a tear since July gaining more than 30%